FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.
What happened
FDA inspected the drug manufacturing facility from December 4 to 8, 2023. It found that the company had not established scientifically sound specifications and test methods for its over-the-counter drug product, and that its quality unit did not effectively oversee laboratory controls. FDA also cited inadequate microbial testing of a component used in the drugs.
What FDA found
The company lacked scientifically sound release specifications and analytical test methods for critical quality attributes; for an OTC product labeled with two active ingredients, its certificate of analysis had only one assay specification and result.
21 CFR 211.160(b)The company did not adequately test a component used in its drugs for objectionable microorganisms; it tested only total aerobic microbial count and did not specify microbial identification of isolates.
21 CFR 211.160(b)The quality control unit did not effectively exercise its responsibility and authority to approve or reject components, materials, and drug products or to oversee establishment of laboratory controls.
21 CFR 211.22(a)
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, including a comprehensive laboratory assessment and quality-unit remediation plan. If it cannot complete actions in that time, it must state reasons and a completion schedule.
Who should pay attention
- brands that buy OTC drug products from this manufacturer
- distributors and importers of Chinese-made drugs
- quality teams at contract manufacturers and suppliers of drug components
This is a summary. Read the original letter on fda.gov.